Concerns Build Over Surgisphere’s COVID-19 Dataset

NEJM and The Lancet issue expressions of concern as researchers question where the company got its data on thousands of coronavirus patients.

Written byCatherine Offord
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

ABOVE: © ISTOCK.COM, WHYFRAMESTUDIO

Update (June 3): The World Health Organization today announced that it would be resuming hydroxychloroquine testing in its Solidarity Trial, following widespread criticism of The Lancet paper and the dataset it was based on.

Scientists are questioning the validity of two influential studies of COVID-19 patients as concerns grow about the provenance of the dataset underpinning them. Despite assurances from Surgisphere Corporation, an Illinois-based company that owns the data, hundreds of researchers have now signed open letters to The Lancet and the New England Journal of Medicine (NEJM), voicing their concerns. Today, NEJM and The Lancet issued expressions of concern about the reliability of the papers’ conclusions.

“Recently, substantive concerns have been raised about the quality of the information in that database,” writes NEJM editor-in-chief Eric Rubin in the expression of concern. “We have asked the authors to provide evidence that the data are reliable. In ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo